Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Abeona Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Vish Seshadri

İcra Kurulu Başkanı

US$2.8m

Toplam tazminat

CEO maaş yüzdesi	19.5%
CEO görev süresi	3yrs
CEO sahipliği	2.1%
Yönetim ortalama görev süresi	3yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Aug 16

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Mar 31

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Oct 19

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Oct 04

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Aug 11

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Jul 20

Abeona crashes 21% as reverse stock split takes effect

Jul 05

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Mar 02

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Aug 17

Abeona Therapeutics shares rise after letter to stockholders

May 26

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Apr 28

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Feb 21

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Dec 15

CEO Tazminat Analizi

Vish Seshadri'un ücretlendirmesi Abeona Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$77m
Dec 31 2023	US$3m	US$555k	-US$54m
Sep 30 2023	n/a	n/a	-US$45m
Jun 30 2023	n/a	n/a	-US$39m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$1m	US$505k	-US$43m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$84m
Mar 31 2022	n/a	n/a	-US$91m
Dec 31 2021	US$2m	US$255k	-US$85m

Tazminat ve Piyasa: Vish 'nin toplam tazminatı ($USD 2.85M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Vish şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Vish Seshadri (48 yo)

3yrs

Görev süresi

US$2,847,442

Tazminat

Dr. Vishwas Seshadri, also known as Vish, Ph.D. & M.B.A., serves as Chief Executive Officer, President and Director at Abeona Therapeutics Inc. since October 15, 2021. He served as the Senior Vice Presiden...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vishwas Seshadri	President	3yrs	US$2.85m	2.09% $ 5.8m
Joseph Vazzano	Chief Financial Officer	2.6yrs	US$1.49m	0.84% $ 2.4m
Brendan O'Malley	Senior VP & General Counsel	4.5yrs	US$1.17m	0.63% $ 1.8m
Brian Kevany	Senior VP	3.3yrs	Veri yok	Veri yok
Gregory Gin	Vice President of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Alison Hardgrove	Chief People Officer	2.8yrs	Veri yok	Veri yok
Jon Voss	VP & Head of Quality	3yrs	Veri yok	Veri yok
Madhav Vasanthavada	Senior VP	1.1yrs	Veri yok	Veri yok
Carl Denny	Senior Vice President of Regulatory Affairs	no data	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: ABEO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vishwas Seshadri	President	3yrs	US$2.85m	2.09% $ 5.8m
Mark Alvino	Independent Director	3.6yrs	US$336.14k	0.17% $ 467.3k
Faith Charles	Independent Director	3.6yrs	US$336.14k	0.26% $ 734.7k
Donald Wuchterl	Independent Director	3.5yrs	US$330.52k	0.26% $ 739.7k
Eric Crombez	Independent Director	less than a year	Veri yok	0.025% $ 71.4k
Christine Berni-Silverstein	Independent Director	4.6yrs	US$324.89k	0.23% $ 629.7k
Leila Alland	Independent Director	3.5yrs	US$336.14k	0.27% $ 764.0k
Steven Gray	Member of Scientific Advisory Board	7.5yrs	Veri yok	Veri yok
Erika Augustine	Member of Scientific Advisory Board	7.5yrs	Veri yok	Veri yok
Jonathon Mink	Member of Scientific Advisory Board	7.5yrs	Veri yok	Veri yok
John Cooper	Member of Scientific Advisory Board	7.5yrs	Veri yok	Veri yok
Michael Amoroso	Chairman of the Board	3.6yrs	US$351.14k	0.33% $ 932.6k

3.6yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ABEO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Abeona Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Abeona Therapeutics Inc. Announces Board Appointments

Independent Director notifies of intention to sell stock

Independent Director recently bought US$52k worth of stock

Abeona Therapeutics Inc., Annual General Meeting, Apr 24, 2024

President recently bought US$88k worth of stock

Abeona Therapeutics Inc. Appoints Madhav Vasanthavada as Chief Commercial Officer

Recent updates

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Consensus revenue estimates decrease by 33%, EPS upgraded

Abeona Therapeutics Inc. Announces Board Appointments

Independent Director notifies of intention to sell stock

Independent Director recently bought US$52k worth of stock

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$1.36 loss

Abeona Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $75.000174 million.

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Price target decreased by 7.1% to US$19.50

Consensus revenue estimates fall by 10%

New major risk - Financial position

Abeona Therapeutics Inc. Provides Regulatory Update on Pz-Cel

Abeona Therapeutics Inc., Annual General Meeting, Apr 24, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

President recently bought US$88k worth of stock

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Forecast to breakeven in 2026

Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Forecast to breakeven in 2025

New minor risk - Share price stability

New minor risk - Insider selling

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Inc. Appoints Madhav Vasanthavada as Chief Commercial Officer

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$2.08 loss in 2Q 2022)

Abeona Therapeutics Announces Additional Phase 3 Viital Study Results for Eb-101 Presented At the International Societies for Investigative Dermatology 2023 Meeting

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Price target increased to US$29.00

High number of new and inexperienced directors

Abeona Therapeutics Inc. announced that it expects to receive $35.000004 million in funding from Adage Capital Management, L.P., Armistice Capital LLC, EcoR1 Capital, LLC, Nantahala Capital Management, LLC, Deerfield Management Company, L.P. Series C and other investors

Consensus forecasts updated

Abeona Therapeutics Inc. announced that it expects to receive $35.000004 million in funding from Adage Capital Management, L.P., Armistice Capital LLC, EcoR1 Capital, LLC, Nantahala Capital Management, LLC, Deerfield Management Company, L.P. Series C

Abeona Therapeutics Inc. Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Abeona Therapeutics Inc. Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Consensus forecasts updated

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Abeona Therapeutics Inc., Annual General Meeting, Aug 17, 2022

Consensus forecasts updated

Abeona crashes 21% as reverse stock split takes effect

Consensus revenue estimates increase by 95%

Nasdaq Grants Second 180-Day Period to Abeona Therapeutics to Regain Compliance with Minimum Bid Price Rule

Price target decreased to US$2.00

High number of new and inexperienced directors

Consensus forecasts updated

Abeona Therapeutics Inc. Reports Goodwill Impairment Charge for the Fourth Quarter Ended December 31, 2021

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Price target decreased to US$4.50

High number of new directors

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Abeona Therapeutics Inc. Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 Viital Study for Recessive Dystrophic Epidermolysis Bullosa

Price target decreased to US$4.67

Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000E Value Index

Abeona Therapeutics shares rise after letter to stockholders

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

President notifies of intention to sell stock

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Independent Director recently sold US$310k worth of stock

Independent Director exercised options and sold US$342k worth of stock

Abeona Therapeutics Inc. Announces New Positive Data from Two Ongoing Phase 1/2 Clinical Trials of its Investigational AAV-Based Gene Therapies ABO-102 and ABO-101 in MPS IIIA and MPS IIIB

New 90-day high: US$2.34